Pfizer: Lymphoma, Follicular trials
The registry lists 22 Lymphoma, Follicular studies with Pfizer as lead sponsor. 1 are open to participants now and 16 have results posted.
Phase 1 6Phase 2 6Phase 3 10(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular LymphomaRecruitingNCT03460977Phase 1
- Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia AreataCompletedNCT02974868Phase 2Results posted
- Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular LymphomaTerminatedNCT02855359Phase 2Results posted
- Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic DermatitisCompletedNCT02780167Phase 2Results posted
- Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell LymphomaTerminatedNCT02592876Phase 2Results posted
- A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)CompletedNCT02213263Phase 3Results posted
- Study to Evaluate PF-04965842 in Patients With Moderate to Severe PsoriasisTerminatedNCT02201524Phase 2Results posted
- Tofacitinib Ointment For Chronic Plaque PsoriasisCompletedNCT01831466Phase 2Results posted
- A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque PsoriasisCompletedNCT01815424Phase 3Results posted
- A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic ArthritisCompletedNCT01519089Phase 3Results posted
- A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque PsoriasisCompletedNCT01309737Phase 3Results posted
- A Study Of PF-05082566 As A Single Agent And In Combination With RituximabCompletedNCT01307267Phase 1Results posted
- A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque PsoriasisCompletedNCT01276639Phase 3Results posted
- A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque PsoriasisCompletedNCT01241591Phase 3Results posted
- A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque PsoriasisCompletedNCT01186744Phase 3Results posted
- A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque PsoriasisTerminatedNCT01163253Phase 3Results posted
- Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)TerminatedNCT00562965Phase 3Results posted
- A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin LymphomaTerminatedNCT02702141Phase 1
- Safety Study of SEA-CD40 in Cancer PatientsTerminatedNCT02376699Phase 1
- Safety Study of SGN-CD70A in Cancer PatientsCompletedNCT02216890Phase 1
- A Safety Study of SGN-CD19A for B-Cell LymphomaCompletedNCT01786135Phase 1
- Study Evaluating ReFacto AF in Severe Hemophilia ACompletedNCT00037544Phase 3